FDA approves Lilly's new combination therapy for advanced breast cancer

The U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer.

The therapy pairs two agents to target disease that has progressed despite prior treatment. The approval follows clinical studies that demonstrated its safety and efficacy in the indicated population.

The decision adds a new option for oncologists and expands Lilly’s oncology portfolio, potentially influencing treatment guidelines and patient care.